secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001829126-23-000571
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharma receives Nasdaq delisting notice for missing annual shareholder meeting
--------------------------------------------------------------------------------

- Nasdaq notice for failure to hold annual meeting within 12 months of Dec 31, 2021 fiscal year end.
- No immediate effect on listing; company has 45 days to submit a compliance plan.
- If plan accepted, exception may be granted until June 29, 2023 to regain compliance.
- Failure to regain compliance could lead to delisting of TTNP common stock from Nasdaq.
- Company intends to schedule annual meeting and submit plan to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912623000571/0001829126-23-000571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912623000571/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-23-000571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer